Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Industry Analysis and Forecast (2019-2026): By indication type, treatment type,…

The Platelet Rich Plasma and Stem Cell Alopecia Treatment market is expected to grow from US$ XXBn in 2018 to USD XX Bn by 2026, at a CAGR of 6.1% during the forecast period.

Platelet-rich plasma (PRP) a new biotechnology, is the product of a heightened interest in cell-based therapy and tissue engineering. This therapy is defined as an autologous preparation of plasma with concentrated platelets.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment MarketGlobal Atomic Force Microscopes Market Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Drivers and RestrainsFactors contributing to the growth of this market include rise in disease awareness, treatment rate, and growing adoption of novel treatment therapies providing positive patient outcome. Moreover, lower incidences of negative side effects of this therapy are anticipated to fuel demand for platelet rich plasma (PRP) and stem cell therapy.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/36142

Treatment options for androgenic alopecia are limited and include topical minoxidil and oral finasteride (FDA approved) alone or in combination. Several reported side effects such as headache and increase in body hair are there for minoxidil whereas loss of libido has been reported with oral finasteride are considered to be major restraint to the global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market.

Hair loss is one of the significant factors that will foster the global hair transplant market growth over the projection period. Increasing patient pool in developing countries significant success rate and hair transplant procedures coupled with innovative technologies also help hair transplant market to grow seamlessly in the near future.

Advance treatments for alopecia are enhanced by dermatologists and patients over regular medications, for example, corticosteroids. More prominent inclination for these treatments emerges from proficient and quicker hair regrowth when contrasted with other corticosteroid medications. Furthermore, simplicity of organization of these novel treatments is anticipated to boost the global market.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market by key segments

The stem cell therapy segment has been further classified into bone marrow treatment and adipose treatment. The dermatology clinics segment accounted for 88% of the total market revenue in 2018, owing to its lower therapy cost as compared to hospitals.

About 45% men and 35% women develop androgenic alopecia by 60, which is the highest among all the types of alopecia in the year 2018. A study published in the International Journal of Womens Dermatology in 2019 revealed that the use of PRP to treat androgenic alopecia is promising due to its autologous nature, minimal invasiveness, lack of major side effects, and low cost compared to hair restoration surgery.

Global Systemic Inflammatory Response Syndrome Treatment Market Regional AnalysisNorth America is anticipated to held leading position for global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market . In 2018, XX% of women suffer from androgenetic alopecia in North America. This has led the country to dominate the platelet rich plasma & stem cell alopecia treatment market in North America. The market in Asia Pacific is projected to expand at a significantly high CAGR during the forecast period, owing to the emergence of strong local manufacturers offering various technological advancements for platelet rich plasma & stem cell alopecia treatment at lower prices and increase in awareness among people about these treatment methods. Additionally, highest application of PRP for the treatment of alopecia has been observed in the past few years. This is likely to fuel the market in the region. Furthermore, technological advances and huge numbers of investments in Platelet Rich Plasma Therapies by key players are likely to fuel the global market in the emerging regions such as in china and India.

The objective of the report is to present comprehensive analysis of Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market dynamics, structure by analyzing the market segments, and project the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market size. Clear representation of competitive analysis of key players by Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market make the report investors guide.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/36142

Global Platelet Rich Plasma & Stem Cell Alopecia Treatment Market, by Treatment

Platelet Rich Plasma Therapies Stem Cell TherapyGlobal Platelet Rich Plasma & Stem Cell Alopecia Treatment Market, by Indication

Androgenic Alopecia Congenital Alopecia Cicatricial or Scarring AlopeciaGlobal Platelet Rich Plasma & Stem Cell Alopecia Treatment Market, by Type

Men womenKey players operating on Global Platelet Rich Plasma & Stem Cell Alopecia Treatment Market

Kerastem Eclipse Regen Lab SA Restore Hair Replicel LifeScience Histogen Inc. Glofinn Oy Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Anderson Center for Hair, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, Virginia Surgical Center, Hair Transplant Institute of Miami, Colorado Surgical Center & Hair Institute.

MAJOR TOC OF THE REPORT

Chapter One: Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Competition, by Players

Chapter Four: Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size by Regions

Chapter Five: North America Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Countries

Chapter Six: Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Countries

Chapter Seven: Asia-Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Countries

Chapter Eight: South America Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Platelet Rich Plasma and Stem Cell Alopecia Treatment by Countries

Chapter Ten: Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Segment by Type

Chapter Eleven: Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Segment by Application

Chapter Twelve: Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Report at:https://www.maximizemarketresearch.com/market-report/global-platelet-rich-plasma-and-stem-cell-alopecia-treatment-market/36142/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Go here to see the original:
Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Industry Analysis and Forecast (2019-2026): By indication type, treatment type,...

Potential Impact of COVID-19 on Rheumatoid Arthritis Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2034 2018 to 2028 -…

The presented market report on the global Rheumatoid Arthritis Stem Cell Therapy market published by Fact.MR is a comprehensive analysis of the leading parameters that are likely to determine the growth of the Rheumatoid Arthritis Stem Cell Therapy market in the forthcoming decade. Further, the study dives in deep to investigate the micro and macro-economic factors that are projected to influence the global scenario of the Rheumatoid Arthritis Stem Cell Therapy market during the forecast period (2019-2029).

The market study reveals that the Rheumatoid Arthritis Stem Cell Therapy market is expected to grow at a CAGR of ~XX% and reach a value of ~USXX by the end of 2029. The report examines the current trends, growth opportunities, restraints, and market drivers that are projected to influence the overall dynamics of the Rheumatoid Arthritis Stem Cell Therapy market in the assessment period. The market study predicts the course of the global Rheumatoid Arthritis Stem Cell Therapy market post the COVID-19 pandemic and offers resourceful insights to market players pertaining to their business continuity strategies and more.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

Rheumatoid Arthritis Stem Cell Therapy Market Segmentation

The report bifurcates the Rheumatoid Arthritis Stem Cell Therapy market into multiple segments to provide a clear picture of the Rheumatoid Arthritis Stem Cell Therapy market at a granular level. The key segments covered in the report include region, product type, application, and more.

Competitive landscape

The growth projection of each of these segments and sub-segments is accurately tracked in the report along with east-to-understand graphs and tables. Further, the market share, size, value, and Y-o-Y growth of the Rheumatoid Arthritis Stem Cell Therapy market segments are included in the report.

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Essential Takeaways from the Rheumatoid Arthritis Stem Cell Therapy Market Report

Important queries related to the Rheumatoid Arthritis Stem Cell Therapy market addressed in the report:

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Why Choose Fact.MR

More here:
Potential Impact of COVID-19 on Rheumatoid Arthritis Stem Cell Therapy Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2034 2018 to 2028 -...

InnoCan Pharma, TAU Ink Deal To Work On CBD-Based Treatment For COVID-19 | Health News – NoCamels – Israeli Innovation News

Israels InnoCan Pharma, a company specializing in developing novel therapeutics using cannabinoids, has entered into an agreement with Ramot, the technology transfer arm of Tel Aviv University, to develop a novel approach to treat COVID-19 by using cannabidiol (CBD) loaded exosomes.

Exosomes are small particles created when stem cells are multiplied. They can act as homing missiles, targeting specific damaged organs and also have an important role in cell-to-cell communication.

InnoCan will join a team led by Professor Daniel Offen, a researcher specializing in neuroscience and exosome technology at Tel Aviv University, to collaborate on the development of a cell therapy product, based on his work in the field.

The two groups will collaborate on a novel, exosome-based technology that targets central nervous system (CNS) indications and COVID-19, the disease caused by the novel coronavirus, they said in a statement.

CBD-loaded exosomes hold the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells.

When cell healing properties of the exosomes are combined with the anti-inflammatory properties of CBD, it is expected to reach this high synergetic effect, according to InnoCan.

InnoCan has agreed to fund the research in the aggregate amount of about $450,000 in the first stage.

The product will be administered by inhalation, InnoCan said, and will be tested against a variety of lung infections.

The research results may also be beneficial to additional treatments for Central Nerve System ( CNS ) indications, such as epilepsy and Alzheimers Disease, the company said.

The agreement gives InnoCan the option to receive an exclusive global royalty-bearing license to Ramots background tech and the research results to allow InnoCan to develop and manufacture this potential treatment for COVID-19 and other respiratory illnesses. If InnoCan decides to exercise this option, the two companies have agreed to negotiate the license agreement, according to predefined commercial terms outlined in the agreement.

Go here to read the rest:
InnoCan Pharma, TAU Ink Deal To Work On CBD-Based Treatment For COVID-19 | Health News - NoCamels - Israeli Innovation News

Study of Stem Cell Therapy for Highly Active RRMS Honored by CR Forum – Multiple Sclerosis News Today

The MISTPhase 2 clinical trial, supporting the potential of hematopoietic (blood cell-producing)stem cell transplant (HSCT) to significantly slow disability progression in highly activerelapsing-remitting multiple sclerosis (RRMS)patients, has received a Distinguished Clinical Research Achievement Award from the Clinical Research (CR) Forum.

Five years after the transplant, most treated patients showed no further disease progression or activity, a press release announcing the honor stated.

The CR Forum is a nonprofit association of clinical research experts and leaders at leading academic health centers in the U.S. Each year, it recognizes exceptional studies through itsTop 10 Clinical Research Achievement Awards.

Two of these awards are considered Distinguished Clinical Research Achievement Awards, and highlight clinical studies whose creativity, innovation, and novelty carry great promise for patients. Each carries a cash prize of $5,000.

One Distinguished Award wasgiven to Richard Burt, MD, the chief of Northwestern Medicinesimmunotherapy for autoimmune diseases division,who pioneered the use of HSCT to treat relapsing MS.

His project is titled Hematopoietic Stem Cell Transplantation for Frequently Relapsing Multiple Sclerosis.

HSCT is an intensive therapy that rebuilds a patients immune system. The first step is to collect a patients own (meaning, autologous) healthy hematopoietic stem cellsfrom the bone marrow, followed by a fairly non-aggressive combination of chemotherapy (non-myeloablative) that kills the rest of the patients immune cells.

The hematopoieticstem cellsare then infused back to the patient to generate a new, and healthy immune system.

The MISTPhase 2 clinical trial (NCT00273364), led by Burt in collaboration with an international team of researchers, compared the efficacy of non-myeloablative HSCT to continuous disease-modifying therapy (DMT) use.

A total of 110 patients, ages 18 to 55, with aggressive RRMS were enrolled. All had at least two relapses while undergoing treatment with a DMT in the previous year.

Patients were equally randomized to a chemotherapy regimen plus a suppressant of the immune system (to prevent HSCT rejection), followed byHSCT (55 patients), or as a control group to a stronger DMT, different from the one they had taken the previous year (55 patients).

The control group was given a wide selection of DMTs to choose among, including interferons,Tysabri(natalizumab),Tecfidera(dimethyl fumerate),Gilenya(fingolimod),Copaxone(glatiramer acetate), andNovantrone(mitoxantrone).Other immune therapies in the control group included corticosteroids, Cytoxan (cyclophosphamide), andrituximab.

Results, published in the journal JAMA in 2019,showed that significantly fewer patients in the HSCT group experienced disease progression (three out of 52) after one year compared to those in the DMT group (34 out of 51).

Progression did increase over time, but at a significantly lesser rate in the HSCT group.

Over the first year post-transplant, 36 patients in the DMT group experienced a relapse, while one patient relapsed in the HSCT group. During this period, scores on the Expanded Disability Status Scale(EDSS; a method of quantifying disability in MS with higher scores corresponding to greater disability) decreased in the HSCT group, dropping from 3.38 to 2.36. Scores over that year in the DMT group the score rose from 3.31 to 3.98.

Patients in the HSCT group also showed significantly less disease activity on MRI scans after one year.

No patient died during the study, and no potential life-threatening events (cardiac failure or generalized infection affecting multiple organs, called sepsis) occurred in the HSCT group.

HSCTs use is also thought to translate to a lower financial burden on both private insurance companies and public health, the release states. HSCT is estimated to have a one-time cost of around $98,000, while other MS therapies carry a yearly cost of around $80,000 and are required throughout a persons lifetime.

Most importantly, the CR Forum notes, HSCT achieved for the first time what no other therapy has the ability to nearly halt disease progression and relapses.

Most patients show no further progressive disability or evidence of new disease activity over 5 years. HSCT is markedly superior to the current, ongoing drug therapies in preventing relapses, slowing disease progression, decreasing the burden of disease in the brain, and improving a patients quality of life, the release states .

The other Distinguished Clinical Research Achievement Award was given to the CREDENCE Phase 3 trial, led by Kenneth Mahaffey, a professor of medicine(cardiovascular medicine) at theStanford University MedicalCenter.

This randomized study (NCT0206579) enrolled 4,401 people with type 2 diabetes and kidney disease due to diabetes. Patients were randomized to canagliflozin (sold as Invokana, among other brand names) or a placebo.

Results showed that canagliflozin lowered the risk of kidney failure by 30% in these patients, marking the first time a therapy has lowered the risk of kidney failure in this patient group. Treatment with canagliflozin lowered the risk of death due to heart attacks and strokes, as well as the rate of hospitalization due to heart failure.

Finally, The Herbert Pardes Clinical Research Excellence Award, which has a $7,500 prize, when to researchers who developed and studied an innovative skin-like sensor that is placed on an infants chest and foot to allow closer monitoring of health using wireless technology. According to the release, such monitoring dramatically improves medical outcomes for the most fragile patients, like premature infants.

The study was led by John Rogers and his engineeringteam at Northwestern Feinberg School of Medicine in collaboration with clinicians.

This years award winners demonstrate the immense value of our nations investment in clinical research, and the direct impact of that work on the health of millions of people in the United States, Harry P. Selker, MD, CR Forum board chair and dean of the Clinical and Translational Science Instituteat Tufts University, said in the release.

For many, these innovative studies and related clinical trials may represent the only hope for surviving a life-threatening disease. They also pave the way to advance new therapies and treatments that improve public health, Selker added.

The full list of the 2020 Top 10 Clinical Research Achievement Awardees is available here.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

Total Posts: 1,053

Patrcia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

Visit link:
Study of Stem Cell Therapy for Highly Active RRMS Honored by CR Forum - Multiple Sclerosis News Today

Preclinical Study Showing Beneficial Effects of Cymerus MSCs in Acute Respiratory Distress Syndrome Accepted for Publication in Leading Peer-Reviewed…

MELBOURNE, Australia, April 17, 2020 (GLOBE NEWSWIRE) --Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that a scientific paper describing the use of Cymerus mesenchymal stem cells (MSCs) in a model of Acute Respiratory Distress Syndrome (ARDS) has been accepted for publication in the American Journal of Respiratory and Critical Care Medicine (AJRCCM).1The AJRCCM, commonly known as The Blue Journal, is widely regarded as the foremost peer-reviewed journal in the field of respiratory and critical care medicine.

Background

The study was conducted in 14 sheep with severe ARDS supported by extracorporeal membrane oxygenation (ECMO), which were given an endobronchial infusion of either Cymerus MSCs (n=7) or placebo (n=7). Animals were monitored and supported for 24 hours, at which time the study concluded.

ARDS is an inflammatory process leading to build-up of fluid in the lungs and respiratory failure. It can occur due to a range of insults, including infection, trauma and inhalation of noxious substances. It has received significant global attention in recent times, as it is one of the most serious complications experienced by patients suffering from COVID-19. ARDS accounts for approximately 10% of all ICU admissions and almost 25% of patients requiring mechanical ventilation, and results in hospital mortality ofup to 46%.2 In addition, survivors of ARDS are often left with severe long-term illness and disability.3

ECMO is a last-line intervention used in patients whose lungs are unable to provide an adequate amount of oxygen to the blood, despite the use of ventilators and other interventions. ECMO circulates blood through an artificial lung, oxygenating the blood before returning it to the patients circulation. ECMO can help support the vital organs in patients with severe ARDS, but it is not in itself a treatment for ARDS and the mortality among patients supported by it remains high.

This study was conducted independently of Cynata by a group of leading academics known as the Combining Extracorporeal Life Support and Cell Therapy in Critical Illness (CELTIC)Investigators, led by Professor John Fraser of the Critical Care Research Group, The Prince Charles Hospital, Brisbane. The study was funded by the Queensland Government, the National Health and Medical Research Council (NHMRC), the Intensive Care Society UK, and the Prince Charles Hospital Foundation.

Key Results

Cymerus MSC treatment was shown to exert a number of important beneficial effects in this study:

There were no statistically significant differences in oxygenation index between groups. The authors of the paper suggested that this may have been due to the severity of the lung injury induced; the fact that the observation period may have been too short to observe all beneficial effects of the treatment; and practical challenges performing these assessments during ECMO.

The authors also observed that a different dose regimen and/or route of administration could lead to further improved outcomes.

The study also found that MSCs adhere to the membranes in the ECMO device, resulting in a significant increase in pressure, and there was a higher incidence of thrombosis in the lungs observed post-mortem. While this did not lead to failure of the ECMO device or other observed adverse events, the study team considered that it could potentially do so, and therefore concluded that they cannot currently recommend the use of MSCs in combination with ECMO. It is important to note that this finding is relevant to MSCs in general (regardless of source), as it is related to the propensity of MSCs to adhere to plastic, but it does not have implications for the treatment of patients with ARDS who are NOT receiving ECMO.

Dr Kilian Kelly, Cynatas Chief Operating Officer, commented:

We are very encouraged by the beneficial effects of Cymerus MSCs on a number of important, clinically-relevant endpoints in this model of ARDS. These results provide valuable guidance on the potential clinical utility of Cymerus MSCs in the treatment of ARDS. It is also very useful to learn more about the practical mechanical challenges associated with administering MSCs at the same time as ECMO, but it is important to note that most patients with ARDS do not receive ECMO. Furthermore, in humans with ARDS who are not receiving ECMO, we expect to be able to administer repeated intravenous infusions of MSCs, which may have advantages compared to the approach that was taken in this preclinical study. We are currently in discussions with leading key opinion leaders about a possible clinical trial in human patients with ARDS, including those who have developed ARDS as a result of the devastating COVID19 pandemic.

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus, a proprietary therapeutic stem cell platform technology. Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynatas lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus MSCs into Phase 2 trials for GvHD, critical limb ischemia and osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of asthma, diabetic wounds, sepsis, heart attack and cytokine release syndrome, a life-threatening condition stemming from cancer immunotherapy.

______________________

1 Millar JE, Bartnikowski N, Passmore MR, et al. Combined Mesenchymal Stromal Cell Therapy and ECMO in ARDS: A Controlled Experimental Study in Sheep. Am J Crit Care Med, 2020.2 Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. Jama. 2016;315(8):788.3 Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364(14):1293-304.

Read the rest here:
Preclinical Study Showing Beneficial Effects of Cymerus MSCs in Acute Respiratory Distress Syndrome Accepted for Publication in Leading Peer-Reviewed...

New Treatment Shows Vision Benefit in Age Related Macular Degeneration – Benzinga

MD Stem Cells reports results for Dry AMD from their clinical study SCOTS - the Stem Cell Ophthalmology Treatment Study. 63% of treated and evaluated eyes achieved improvement in vision while an additional 34% had vision remain stable in follow up. No complications occurred. Results were statistically significant.

Westport, CT, April 18, 2020 --(PR.com)-- Age Related Macular Degeneration - specifically dry AMD - will affect almost 200 million people worldwide in 2020. An approach, pioneered by MD Stem Cells, using bone marrow stem cells from the actual patient has now shown visual improvement for 63% of dry AMD eyes and stability in another 34%, demonstrating statistical significance in helping patients with this blinding disease. Results were recently published in the Medicines Journal - a highly regarded international medical journal. The title of the paper: Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Age-Related Macular Degeneration.

There is no FDA approved medication for treating dry AMD. Certain vitamins may reduce the risk of bleeding or wet AMD. But vitamins do not appear to stop the relentless loss of retinal cells and vision called geographic atrophy (GA) from AMD.

The highlight of the MD Stem Cell report was that 63% of dry AMD eyes treated and followed had vision improvement. This ranged from 2.5% to 44.6% with an average of 27.6% on a scientific vision scale called LogMAR. An additional 34% of eyes remained stable for the follow up period- important because many of the eyes had previously been losing vision. The findings were highly statistically significant with p < 0.001 meaning that the results overwhelmingly met that medical standard and confirming that the BMSC treatment was responsible for the improvements seen.

The Stem Cell Treatment Ophthalmology Study- both SCOTS and SCOTS2 - has been treating many different eye diseases since 2013 using the patients own bone marrow stem cells (BMSC) injected in the orbit around the eye. The study is Institutional Board Approved and National Institutes of Health registered on http://www.clinicaltrials.gov NCT 03011541. The physicians involved with MD Stem Cells now have 14 world class medical and scientific publications primarily reporting their clinical results in ophthalmology. This is vastly more than any other stem cell research group working with eye disease and should be reassuring to patients and health care providers seeking treatment options. Different optic nerve diseases, NAION, LHON, DOA, optic atrophy; as well as several retinal diseases including Retinitis Pigmentosa, Ushers and now AMD have all shown benefit. MD Stem Cells has worked to achieve the safest, most effective approach to dry AMD using BMSC - with gratifying success.

Following multiple patient treatments and over a dozen peer-reviewed papers, our studies have shown that a patients own bone marrow stem cells (BMSC) can have positive effects on different retinal and optic nerve diseases, explains Dr. Levy, CEO and Chief Science Officer for MD Stem Cells. As we have continued the study, other researchers have published numerous papers revealing how this may be occurring: release of exosomes with neurotrophic factors helping neurons and photoreceptors, transfer of cytoplasmic structures such as mitochondria to injured cells, and transdifferentiation of BMSC into neurons.

Dr. Levy concludes: The research has shown that patients with dry AMD choosing to participate in the SCOTS 2 may have a significant likelihood of either improving or stabilizing their vision.

Patients may receive information about SCOTS 2 by emailing stevenlevy@mdstemcells.com, using the contact us page on http://www.mdstemcellscom, or calling 203-423-9494. The Stem Cell Ophthalmology Study 2 is enrolling patients with different retina and optic nerve diseases. MD Stem Cells has no grant support and is not a pharmaceutical company; these are patient sponsored studies and the patients pay for both treatment and travel.

Contact Information:MD Stem CellsSteven Levy MD203-423-9494Contact via Emailwww.mdstemcells.com

Read the full story here: https://www.pr.com/press-release/810435

Press Release Distributed by PR.com

Read more:
New Treatment Shows Vision Benefit in Age Related Macular Degeneration - Benzinga

Stem Cells and Silk Make a New Way to Study the Brain – Tufts Now

More than five million Americans, mostly sixty-five or older, suffer from Alzheimers disease (AD), and that number is expected to triple by 2060, as todays twenty-somethings become seniors. No treatments exist for this devastating disease, and its root causes remain as tangled as the curious brain deformities that German physician Alois Alzheimer first described in 1906.

Now a team of Tufts researchers from the School of Medicine and the School of Engineering has received a five-year, $5 million grant from the National Institute on Aging, part of the National Institutes of Health, to study the role of different cell types and mutations in AD. They will use a unique bioengineered mini brain that realistically simulates the human brain environment for years.

The work, which builds on years of collaboration among the researchers, will overcome two traditional stumbling blocks to such studies: the limited relevance of animal models and the inability of cell culture systems to reproduce the physiology of the human brain. While age is the biggest risk factor for AD, genetics also plays a role. Scientists have uncovered twenty gene variants that increase the risk of AD, said Giuseppina Tesco, professor of neuroscience and lead investigator on the research, who has devoted her career to studying the disease.

Recent studies show that most of the genes that carry these variants are expressed in glial cells, particularly astrocytes and microglial cells. Once dismissed as onlookers in the brain, glia are now front and center in Alzheimers research said glia expert Philip Haydon, a principal investigator on the project. Haydon, the Annetta and Gustav Grisard Professor of Neuroscience, likens these cells to the pit crew for the flashy race-car-like neurons, supporting top performance by, for example, preventing buildup of protein plaques.

But unlike neurons, human glial cells behave very differently from those of other mammals. What we can learn from mouse models is very limited. It is very important to study these genes in human cells, said Tesco. And we need to do this over time. It may take months to see the effect of genetic variation.

The Tufts team will use cells derived from patients with AD as well as healthy subjects, drawing on advanced stem cell technology that makes it possible to reverse engineer human primary cells into induced pluripotent stem cells, which can then differentiate into neurons, astrocytes, and microglia.

These glia and other brain cells will grow on a unique three-dimensional doughnut-shaped scaffold made of porous silk and collagenwhat the researchers have dubbed a mini brain. Bioengineer David Kaplan, Stern Family Professor and a principal investigator on the grant, and his team have spent six years perfecting the mini brain for research on AD, traumatic brain injury, and brain cancer.

This model allows us to put cells where we want, determine ratios of different cells to use in the system, and control interactions, so we can study electrophysiology, synaptic activity, and other functions as the tissue ages, said Kaplan. That control over the long term supports exploration of age-related questions about disease progression and contributes to reproducibility, a scientific pillar. Past experiments using these mini brains have mimicked structural and functional features and neural activity for up to two years.

In contrast, a two-dimensional culture systemlike the proverbial petri dishwont replicate the complexities of multiple cell types and physiologies. And organoidssimplified organs in miniature now in vogueare subject to cellular death after a few weeks or months.

To complement the in vitro studies with the scaffolds, scientists in Haydons lab will transplant some of the human cells, both mutated and normal, into mice. As they grow, the human glia cells will replace the mouse cells, giving researchers an opportunity to study human brain function. This is the first step towards translational studies, said Haydon.

The grant complements donations from Tufts alumni, parents, friends, and other private individuals who have experienced the pain of Alzheimers disease in their own lives. Donor dollars really got some of our early, exploratory work up and running, said Haydon. Now we are building on that.

The NIH support is a bright spot at a time when COVID-19 has forced Tufts scientists, like their peers around the world, to halt laboratory research, sometimes losing years of work.

Tesco said that while it is difficult to be away from her lab, safety is more important than anything else. Im from Italy, where we have more than 22,000 deaths, she said. Being healthy and having the possibility to continue to do some work, I feel lucky. Well be in the best position possible when were ready to start because well be able to start something completely new and very exciting.

Kim Thurler can be reached at kimberly.thurler@tufts.edu.

See original here:
Stem Cells and Silk Make a New Way to Study the Brain - Tufts Now

A Passover Prayer of Gratitude and Hope – Thrive Global

On Sunday February 25th, I connected on an international flight from Dallas to Israel. Milan, Italy was the city where our flight connected.As we passed through the airport, we were greeted by five people wearing hazmat suits and checking the temperatures of every person passing through.

On Tuesday, February 27th, I received my 8thstem cell infusion as part of my MS treatment program at Hadassah Medical Organization (HMO) in Jerusalem, operated by Hadassah, The Womens Zionist Organization of America, Inc. (HWZOA).

HMO Sr. Neurologist Dr. Dimitrios Karussis, whose revolutionary stem cell therapy has been my treatment protocol, has been my beacon of hope. He gave me back my life.

We were back in Dallas by Thursday, February 29th. We arrived within a week of Italy closing the Milan airport. I was treated two weeks before Israel required a 2-week quarantine period for anyone traveling into the country.

I returned to Dallas just two weeks before my son Zachs wedding.Until this treatment, my MS symptoms had gotten so bad, I was unable to walk through my house, even with a walker. When I returned, I was able to walk again on the treadmill for 5 minutes. That was a gift that HMO made possible.

The Talmud says that if you save one life, that you save the world.HMO saved my life, and gave me joy I could never have had without their help. As I danced with my son at his wedding recently, I cried. I wished that every person who has ever made a donation to Hadassah Medical Organization could know the difference you are making in the lives of people like myself.

This Passover, my husband David and I had our Seder at home with just the two of us. We added to the traditional prayers two additional ones. First, we pray for your health at this difficult time in our country and the world. The second will be the Mi Shebeirach, the traditional Jewish prayer of healing.

Ive experienced the renewal of body and spirit.I now hope to make my life a blessing by volunteering for Hadassah and volunteering at Dallas Childrens Hospital to give their young patients a reason to smile and to hope.

Thank you, Hadassah for everything youve done for me personally, and for the healing you do every day for the land and people of Israel.

Watch MS patient Malia Litman dance at her sons wedding

Learn how MS patient Malia Litman got her life back

Learn more about Hadassah Medical Organization

Learn more about Dr. Dimitrios Karussis and his revolutionary stem cell treatment

CBS/Dallas News coverage of Malia Litmans MS treatment

Follow ushereand subscribeherefor all the latest news on how you can keep Thriving.

Stay up to date or catch-up on all our podcasts with Arianna Huffingtonhere.

See original here:
A Passover Prayer of Gratitude and Hope - Thrive Global

A Realist Who Believes in Miracles – Thrive Global

In 1994, I thought the biggest challenge in life would be finding a balance between a career as a Senior Trial Partner at a big Dallas firm and raising three children. In 1999, it became clear that the real challenge in my life was much more ominous. I was diagnosed with Multiple Sclerosis. There was no explanation as to why I contracted this devastating disease, what symptoms I would develop, or how fast I would become disabled. Would I be confined to a wheelchair or a bed? Would I become blind or simply have double vision? Would I have pain or just tingling? Would I die? I already had bladder problems, but would I also face bowel dysfunction? Over 2.5 million people are afflicted with MS, so why hasnt anyone found a cure? How could drug companies justify charging over $60,000 a year for medicines that dont improve a patients condition?

For the next fifteen years, I managed the kids and the disease with relative success. I learned what a bladder spasm is and the true definition of the word urgency. I learned that my husband really meant it when he said in sickness and health. I learned that pain from MS included the pain associated with doing a face plant into a door, and spilling boiling water on my leg but being unable to remove my pants before suffering 2nd degree burns. I learned that there were a few advantages to having MS, including speeding through airport security lines because I was in a wheelchair, and always being able to find a parking space.

In 2014 I fell and broke my leg. I was in a wheelchair for 6 weeks. It became obvious that it was time to become more aggressive with treatments. After scouring the internet for every treatment for MS in the world, I identified Dr. Dimitrios Karussis at Hadassah Medical Organization in Israel as my best hope. His approach was still experimental. He used the patients own stem cells, obtained through bone marrow extraction, grew the cells, and then infused the cells through a spinal tap.

After eight infusions the benefits of the treatment are unmistakable. Because I still walk with a walker, people realize that Im not cured. What they dont know is that I have my life back. Ive written three books, volunteer regularly at a hospital, travel around the country to raise awareness and financial support for the incredible work of Hadassah, the Womens Zionist Organization of America, Inc. (HWZOA) who operate Hadassah Hospital in Israel. I cook every week for my daughter in medical school. I have attended the graduation ceremonies of each of my three children from college, and I attended the wedding of my oldest son recently. This past year, we celebrated Thanksgiving at my house with 37 relatives.

Having MS has allowed me to stop sweating the small stuff. I have come to realize that what makes me happiest is making others happy. At the Dallas Childrens Hospital where I volunteer, my disability gives me the advantage of having an immediate connection to the kids. Making people smile is the best job at the hospital.

David Ben Gurion said: In Israel, in order to be a realist, you must believe in miracles.

I am a realist. I didnt simply wish to be cured of MS. I researched the possible options for treatment and used my best judgment to select one. Dr. Karussis is also a realist. Hes devoted over 30 years researching stem cell treatment of neurological diseases. He has published more than 120 peer reviewed scientific papers, given more than 150 lectures, served on editorial boards of major medical journals, was elected as the President of the Israeli Neuroimmunological Society and hosted an International Neurological Meeting. He has published the amazing results of the stem cell therapy he formulated for the treatment of MS and ALS.

I also believe in miracles. The miracle is that the people of Hadassah Hospital in Israel have given of their time, talent, and money to make this treatment possible and available to me. The miracle is that studies that I volunteered for twenty years ago in Dallas made me an attractive candidate for Dr. Karussis research. The miracle is that the Israeli Ministry of Health approved me to be treated in their Compassionate Care program. The miracle is that all MS patients can now have hope that an effective treatment is here and Hadassah Hospital is sharing it with the world.

VIDEO LINKS:

Watch MS patient Malia Litman dance at her sons wedding

Learn how MS patient Malia Litman got her life back

Learn more about Hadassah Medical Organization

Learn more about Dr. Dimitrios Karussis and his revolutionary stem cell treatment

CBS/Dallas News coverage of Malia Litmans MS treatment

Follow ushereand subscribeherefor all the latest news on how you can keep Thriving.

Stay up to date or catch-up on all our podcasts with Arianna Huffingtonhere.

Read the rest here:
A Realist Who Believes in Miracles - Thrive Global

HIV/AIDS cure: 4 alternative treatments that can help control the disease as scientists search for the ‘real cure’ – EconoTimes

Doctors and scientists are still trying to find a cure for HIV/AIDS ailment. But even so, a person afflicted with this disease still has a chance to live normally since there are treatments and anti-viral drugs that can help in suppressing the human immunodeficiency virus.

Although they are not really the HIV/AIDS cure that the world is searching for, they can at least minimize the effects and progression of the disease. There is no cure yet as of this time, but luckily, some techniques and procedures are available today to make patients live comfortably and longer.

Shock and kill method

The shock and kill technique may sound like one of those tactics used in the military, but this is actually one of the procedures that scientists using today in their bid to find a cure for AIDS. HIV can hide and remain silent in the body as long as the patient takes antiretroviral therapy.

However, once he or she stops the therapy, the fatal virus will reactivate, multiply, and then eventually spread in the body again. The Shock and Kill are used to wake up the dormant virus, and once they are all awake, they will be killed; thus, the whole group of the HIV will be destroyed all at once and in one go. The downside is that when one virus survives, it can multiply again and live in the patients body.

The Lock and Block method

This method traps the virus in its reservoir cell so it will stay there and will not be reactivated. The HIV is still in the body, but since it was trapped, it cannot come out and multiply, so the disease is controlled.

Stem-Cell Transplant

This is not considered as HIV/AIDS cure, yet even if it was reported that two patients used this stem-cell therapy method and were cured. The reason why this is not yet listed as a cure is because not all of those who have the virus responded well to this treatment. The same method was tried on other patients, but only two have gotten rid of the HIV virus in their body, which caused their AIDS illness.

Read more:
HIV/AIDS cure: 4 alternative treatments that can help control the disease as scientists search for the 'real cure' - EconoTimes